Phase II Study Supports Potential for Genentech ’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma
PharmaPoint: $26.71 Billion Non-Small Cell Lung Cancer (NSCLC) Market - Global Drug Forecast and Analysis to 2025 - Research and Markets
Clovis Oncology Announces 2016 Operating Results
U.S. Obtains Records in Lobbyist Probe -- WSJ
FBI Searches for Possible Accomplices in Probe of Fallen K Street Lobbyist
Internationally Renowned City of Hope Scientist Arthur D. Riggs, Ph.D., Named Samuel Rahbar Chair in Diabetes & Drug Discovery
ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences
Roche Unfazed by Trump's Drug-Price Comments as Profit Rises -- 2nd Update
Genentech DNA reported strong first-quarter revenue and earnings growth compared with the year-ago period, and we are sticking with our fair value estimate. As the company warned at its investor meeting in March, quarter-over-quarter product sales growth was stagnant, while total revenue growth ...
Genentech DNA continues to focus attention on its commercial lineup, making its slimmer early-stage pipeline not worrisome yet. The biotech firm has additional clinical trials and hopes to expand indications for each of its largest products, including Avastin, Herceptin, and Rituxan. According to ...